Healthplus.ai vs Luminare
Two vendors who both think this category measures the wrong thing, for different reasons. Healthplus.ai says the problem is calibration rather than discrimination, and its published evaluation is the most methodologically complete in this category, treating the fact that a model moving between hospitals misestimates absolute risk as the central issue rather than a footnote. Luminare says prediction was never the constraint at all: hospitals already know who is at risk and fail at the bundle and the workflow that follow, and it publishes the best commercial disclosure and implementation ladder in the lane. Both critiques are correct and they compound. A miscalibrated score firing into a ward that cannot act on it is the actual state of sepsis screening in most hospitals, and neither vendor alone fixes both halves.
- The published evaluation is the most methodologically complete in this category, appearing in a regional journal of a major medical publisher rather than in vendor material.
- Calibration is treated as the central problem rather than discrimination, which is the right emphasis for a model that will move between institutions.
- The model class is named and the certification carries an adjunctive constraint, so intended use is written down rather than implied.
- Its founding argument is that prediction was never the constraint, and it builds around intervention, bundle completion and workflow instead.
- The commercial disclosure is the best in this category and it publishes a genuine implementation ladder with timelines attached.
- The mechanism is described plainly enough that you can tell exactly what the product does, which is rare in a lane full of proprietary scores.
Side by Side
| Axis | H Healthplus.ai |
L Luminare |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Inpatient Deterioration & Risk Monitoring page.
The regulatory positions differ and are not equivalent: one is certified in Europe as software as a medical device with an adjunctive constraint, the other is not cleared and states it operates without clearance on the basis of the claims it makes, and it is not currently available for clinical use in the United States in the first case, so check status before evaluating.
Luminare's central argument rests on a review article its own chief executive co authored, which is a stated position rather than independent evidence. Neither publishes an alert burden per patient day.